Home » Newsletters » BioWorld

BioWorld

March 17, 2003

View Archived Issues

Stock Winners and Losers For The Week

Clinical Trial Update: February 2003

Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: February 2003

FDA Submissions, Approvals And Other Actions: February 2003

BioWorld Stock Report For Public Biotechnology Companies

FDA's 'Two-Animal' Rule Becomes Part Of Vical's Anthrax Vaccine Bid

What better way to turn around a company than on the government's dime? Read More

Money Raised Year To Date

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...